Abbott Laboratories has received EU's CE Mark approval for Architect HE4, a blood test designed to help determine whether pelvic masses are benign or cancerous. The company says its product, co-developed with Fujirebio Diagnostics, is the world's first automated HE4 diagnostic. Abbott also filed an application with the FDA seeking 510(k) clearance for the test.

Related Summaries